[1] Nazir S C, Meijers T M, Bartz, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF [J]. JACC Heart Failure, 2018, 6(8): 701-709.
[2] Şengül C, Özveren O. Epicardial adipose tissue: a review of physiology, pathophysiology, and clinical applications [J]. Anadolu Kardiyol Derg, 2013, 13(3): 261-265.
[3] Izgi C. Epicardial adipose tissue: just a predictor or a local player for coronary atherosclerosis? [J]. Anatol J Cardiol, 2015, 15(5): 360-362.
[4] Cherian S, Lopaschuk G D, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease [J]. Am J Physiol Endocrinol Metab, 2012, 303(8): E937-E949.
[5] Patel V B, Shah S, Verma S, et al. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease [J]. Heart Fail Rev, 2017, 22(6): 889-902.
[6] Fitzgibbons T P, Czech M P. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations [J]. J Am Heart Assoc, 2014, 3(2): e000582.
[7] Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue [J]. J Am Coll Cardiol, 2011, 58(5), 248–255.
[8] Patel V B, Oudit G Y. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity [J]. Diabetes, 2016, 65(2): 85-95.
[9] Marrie R A, Garland A, Schaffer S A, et al. Traditional risk factors may not explain increased incidence of myocardial infarction in MS [J]. Neurology, 2019, 92(14), e1624–e1633.
[10] Uysal F, Akbal E, Akbal A, et al, Epicardial adipose tissue is increased in patients with inflammatory bowel disease [J]. J Ultrasound Med, 2016, 35(9): 1859-1864.
[11] Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium [J]. J Am Coll Cardiol, 2018, 71(20): 2360-2372.
[12] Hirata Y, Tabata M, Kurobe H, et a1. Coronary atherosclerosis is associated with macrophage polarization in cpicardial adipose-tissue [J].J Am Coll Cardiol, 201l, 58(3): 248-255.
[13] Huang W H, Xue Y J, Zhou Y J, et al. KLF7 promotes macrophage activation by activating the NF-kβ signaling pathway in epicardial adipose tissue in patients with coronary artery disease [J]. Eur Rev Med Pharmacol Sci, 2020, 24(12): 7002-7014.
[14] Iacobellis G, Mohseni M, Bianco S D, et al. Liraglutide causes large and rapid epicardial fat reduction [J]. Obesity (Silver Spring), 2017, 25(2): 311-316.
[15] Nakanishi K, Fukuda S, Tanaka A, et al. Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation and left ventricular diastolic dysfunction [J]. Can J Cardiol, 2017, 33(11): 1489-1497.
[16] Rabkin S W, Campbell H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis [J]. Obes Rev, 2015, 16(5): 406-415.
[17] Vyas V, Lambiase P. Obesity and atrial fibrillation:epidemiology, pathophysiology and novel therapeutic opportunities [J].Arrhythm Electrophysiol Rev, 2019, 8(1): 28-36.
[18] Wong C X, Sun M T, Odutayo A, et al. Associations of epicardial, abdominal, and overall adiposity with atrial fibrillation [J]. Circ Arrhythm Electrophysiol, 2016, 9(12): e004378.
[19] Zinman B, Wanner C, Lachin J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes [J]. N Engl J Med, 2015, 373(22): 2117-2128.
[20] Marso S P, Daniels G H, Brown F K, et al. Liraglutide and cardiovascular outcomes in yype 2 diabetes [J]. N Engl J Med, 2016, 375(3): 311-322.
[21] Kernan W N, Viscoli C M, Furie K L, et al. Pioglitazone after ischemic stroke or transient ischemic attack [J]. N Engl J Med, 2016, 374(3), 1321-1331.
[22] Mohapradeep M, Shaween A T, Angela M M, et al. Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus-the met-remodel trial [J]. Diabetes, 2018,67: 167.
[23] Zhou J, Massey S, Story D, et al. Metformin: an old drug with new applications [J]. Int J Mol Sci, 2018, 19(10): 2863.
[24] Xie X, Sinha S, Yi Z, et al. Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment [J]. Int J Obes (Lond), 2017, 42(1): 213-220.
[25] Michael J, Benoît J, David M, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model [J]. Diabetes, 2017, 66 (4): 1030-1040.
[26] Yuichiro Y, Shino T, Mamoru Y, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome [J]. Int J Cardiol, 2017, 240: 332-338.
[27] Wu C K, Yeh C F, Chiang J Y, et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial [J]. J Clin Lipidol, 2017, 11(3): 657-666.
[28] Olivier A, Pitt B, Girerd N, et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity [J]. Eur J Heart Fail, 2017, 19(9): 1186-1197.
[29] Inder S A, Brian C, Liu J K, et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial [J]. JACC Heart Failure, 2017, 5(4): 241-252.
[30] Santos R A S, Oudit G Y, Thiago V B, et al. The renin-angiotensin system: going beyond the classical paradigms [J]. Am J Physiol Heart Circ Physiol, 2019, 316(5): H958-H970.
[31] Patel V B, Takawale A, Ramprasath T, et al. Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2 [J]. J Mol Med (Berl), 2015, 93(9): 1003-1013.
[32] Kim Y S, Jeong M H, Cho J G, et al. Protective role of 5-azacytidine on myocardial infarction is associated with modulation of macrophage phenotype and inhibition of fibrosis [J]. J Cell Mol Med, 2014, 18(6): 1018-1027.
[33] Cheng Y Y, Rong J H. Macrophage polarization as a therapeutic target in myocardial infarction [J]. Curr Drug Targets, 2018, 19(6): 651-662.